2026 Q1 Trading Statement¹

Q1 organic revenue growth of +2.2% with North America returning to growth

• Organic revenue growth² of 2.2% with price up 2.4% and volume down 0.2%, weak cold and flu season
  estimated at c.130 bps impact in the quarter 
• North America delivered organic revenue growth of 1.0% despite a weak cold and flu season with
  growth initiatives progressing well 
• Continued strong momentum in Oral Health driven by Sensodyne and parodontax
• Innovation remains a key growth driver. Highlights include continued roll out of innovation across Sensodyne Clinical Platform, Panadol Dual Action and activations across Centrum
• Emerging markets organic revenue growth of 4.3% reflected a weaker macro-economic backdrop and
  performance in Brazil, and soft cold and flu season in APAC and Central & Eastern Europe

Disciplined capital allocation underpinning shareholder returns

• £500m allocated to share buybacks in 2026 with c.36% completed

Reiterating FY 2026 guidance

• FY 2026 organic revenue growth of 3-5% with growth expected to accelerate in remainder of the year 
• Supply chain productivity initiatives continuing to drive gross margin expansion and investment 
• High-single digit adjusted operating profit growth at constant currency

Brian McNamara, Chief Executive Officer, said: 

“We delivered a competitive performance in a challenging market, with North America returning to growth and Oral Health again performing strongly, with innovation and geographic expansion driving double-digit growth in Sensodyne and parodontax. This was tempered by a weak cold and flu season.

We continue to make progress against our other strategic priorities, with our productivity initiatives driving strong gross margin improvement, supporting our confidence in high single-digit operating profit growth for the year. We are also moving forward on the operating model changes we set out in January, which are designed to drive growth and agility.

Looking ahead, while we continue to navigate global geopolitical and macroeconomic uncertainties, we expect growth to accelerate across the balance of the year and remain on track to deliver on our FY guidance.”

2026 Outlook

For FY 2026 the Group continues to expect:

• Organic revenue growth of 3%-5%
• High-single digit adjusted operating profit growth at constant currency
• Net interest c.£255m; Adjusted effective tax rate c.24.5%

Foreign exchange

The Group now expects a broadly neutral foreign exchange translation impact on net revenue and adjusted operating profit respectively, this is based on Bloomberg forward consensus rates averaged over 2026⁵.

Medium term guidance

Haleon’s medium-term guidance is as follows:

• 4-6% annual organic revenue growth
• High-single digit adjusted operating profit growth at constant currency

Presentation for analysts and shareholders

A short presentation followed by Q&A will be hosted by Brian McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial Officer at 9:00am BST (10:00am CEST) on 29 April 2026, which can be accessed at www.haleon.com/investors/.

For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:

UK: +44 (0) 808 189 0158
US: +1 855 979 6654
All other: +44 (0) 203 936 2999
Passcode: 975813

An archived webcast of the presentation will be available later on the day of the results and can be accessed at www.haleon.com/investors.

Financial timetable

Annual General Meeting 29 April 2026 H1 2026 Results 30 July 2026 Q3 2026 Trading Statement 29 October 2026

About Haleon plc

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren are trusted by more than one billion consumers and are recommended by health professionals around the world.

Notes and forward looking statements